Skip to content

Study on the Therapeutic Effect and Mechanism of Bushen Yisui Capsules Against Multiple Sclerosis with Depression Based on Multi-modality Analysis

Study on the Therapeutic Effect and Mechanism of Bushen Yisui Capsules Against Multiple Sclerosis with Depression Based on Multi-modality Analysis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031224
Enrollment
Unknown
Registered
2020-03-25
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis

Interventions

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meets the 2010 McDonald MS diagnostic criteria; 2. Meet the "International Standard for Classification and Diagnosis of Diseases" (ICD-10 diagnostic criteria for mild and moderate depression (F32) depression, first diagnosis, first treatment; 3. HAMD-24 item scale score >= 20 points and < 35 points; 4. Age over 18 years and under 65 years; 5. MRI demyelination site in the skull; 6. Subjects volunteered and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Other treatments were performed before the start of this study; 2. Patients with acute MS who have a cortical state or coma; 3. Suffering from severe heart, liver and kidney dysfunction and other diseases that affect the stability of vital signs; 4. Patients during pregnancy or lactation; 5. People who have a significant tendency to commit suicide; 6. Serious adverse reactions in nuclear magnetic (MRS, DTI) scans that make the examination impossible; 7. In any other situation that the researcher considers unsuitable to participate in this trial, such as failure to cooperate with nuclear magnetic scanning as required by the research; 8. Patients with MS who have entered a relapse period during follow-up.

Design outcomes

Primary

MeasureTime frame
HAMD-24;QIDS;The Kurtzke Expanded Disability Status Scale (EDSS);AIDS;5-HT;IL-1ß;TNF-a;IL-6;IL-2;IL-12;IL-4;IL-13;Fractional Anisotropy, FA;Apparent Diffusion Coefficient, ADC;

Countries

China

Contacts

Public ContactXuesong Zhao

Beijing Tiantan Hospital, Capital Medical University

65835337@qq.com+86 13811347860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026